Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
190
Views
8
CrossRef citations to date
0
Altmetric
Original Research

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Max Schlueter1 IQVIA, Real World Evidence, LondonN1 9JY, UKCorrespondence[email protected]
,
Elaine Finn1 IQVIA, Real World Evidence, LondonN1 9JY, UK
,
Silvia Díaz2 Lilly Spain, Health Outcomes & RWE, Alcobendas28108, Spain
,
Tatiana Dilla2 Lilly Spain, Health Outcomes & RWE, Alcobendas28108, Spain
,
José Inciarte-Mundo3 Lilly Spain, Medical, Alcobendas28108, Spain
&
Walid Fakhouri4 Lilly, Global Patient Reported Outcomes and Real World Evidence (GPORWE) International, Windlesham, SurreyGU20 6PH, UK
Pages 395-403 | Published online: 06 Jun 2019

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sajith Kumar & Bhavani Shankara Bagepally. (2023) Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies. Expert Review of Pharmacoeconomics & Outcomes Research 0:0, pages 1-14.
Read now

Articles from other publishers (7)

S. Sajith Kumar, Madhumitha Haridoss, Krishnamurthy Venkataraman & Bhavani Shankara Bagepally. (2022) Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies. Frontiers in Pharmacology 13.
Crossref
Karina Rossi Bonfiglioli, Licia Maria Henrique da Mota, Ana Cristina de Medeiros Ribeiro, Adriana Maria Kakehasi, Ieda Maria Magalhães Laurindo, Rina Dalva Neubarth Giorgi, Angela Luzia Branco Pinto Duarte, Ana Paula Monteiro Gomides Reis, Mariana Peixoto Guimarães Ubirajara e Silva de Souza, Claiton Viegas Brenol, Geraldo da Rocha Castelar Pinheiro, Cleandro Pires de Albuquerque, Charlles Heldan de Moura Castro, Gustavo Luiz Behrens Pinto, Jose Fernando Verztman, Luciana Feitosa Muniz, Manoel Barros Bertolo, Maria Raquel da Costa Pinto, Paulo Louzada Júnior, Vitor Alves Cruz, Ivanio Alves Pereira, Max Vitor Carioca de Freitas, Bóris Afonso Cruz, Eduardo Paiva, Odirlei Monticielo, José Roberto Provenza & Ricardo Machado Xavier. (2021) Recommendations of the Brazilian Society of Rheumatology for the use of JAK inhibitors in the management of rheumatoid arthritis. Advances in Rheumatology 61:1.
Crossref
A. V. Rudakova, D. G. Tolkacheva & V. D. Sokolova. (2021) Pharmacoeconomic aspects of the therapy for moderate and severe psoriatic arthritis. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology 14:2, pages 116-123.
Crossref
SiNi Li, JianHe Li, LiuBao Peng, YaMin Li & XiaoMin Wan. (2021) Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China. Rheumatology and Therapy 8:2, pages 863-876.
Crossref
Jacopo Angelini, Rossella Talotta, Rossana Roncato, Giulia Fornasier, Giorgia Barbiero, Lisa Dal Cin, Serena Brancati & Francesco Scaglione. (2020) JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future. Biomolecules 10:7, pages 1002.
Crossref
Essam Ezzeldin, Muzaffar Iqbal, Yousif A. Asiri, Azza A Ali, Prawez Alam & Toqa El-Nahhas. (2020) A Hydrophilic Interaction Liquid Chromatography–Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats. Molecules 25:7, pages 1600.
Crossref
. (2019) Baricitinib preferred option in moderate-to-severe RA in Spain. PharmacoEconomics & Outcomes News 830:1, pages 4-4.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.